Martinsried, Germany, October 11, 2012. Proteros biostructures GmbH ("Proteros") today announced the appointment of Mr. Arnd Christ as Chief Financial Officer (CFO) as of 16th of November.
Arnd Christ has more than 12 years of international experience as a CFO in the biotechnology industry, with responsibilities in finance, operations, legal affairs and investor relations. He has successfully conducted a number of financial transactions and has a broad experience in all aspects of accounting and controlling.
Arnd Christ has a successful track record in various biotechnology companies and has most recently worked as Chief Financial Officer at MediGene AG, a listed biotechnology company in Germany. Formerly he served as CFO in biotechnology companies in Germany and Switzerland, as well as Finance Director within the Hoechst AG Group. Mr. Christ earned his master’s degree in Business Administration at Julius Maximilian University Würzburg.
“I am delighted to be joining such an accomplished management team that has built Proteros into a profitable business” commented Arnd Christ. “I am looking forward to helping the team execute on their growth strategy and in particular, the continued expansion into integrated lead discovery collaborations”
Dr. Torsten Neuefeind, Chief Executive Officer and co-founder of Proteros, stated: "We are very pleased to have Arnd join Proteros. His extensive international finance experience in Biotech as well as his solid CFO-background will be a valuable skill set to further support Proteros’ growth strategy in the collaborative research business and in higher value lead discovery partnerships.”
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables "knowledge driven lead engineering" to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients' internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America.
Proteros biostructures GmbH
Dr. Torsten Neuefeind
Phone: +49 (0) 89 7007 61 0